PharmaPoint:人類乳突病毒(HPV)預防疫苗 - EU5個國家的醫藥品預測與市場分析
PharmaPoint: Prophylactic Human Papillomavirus Vaccines - 5EU Drug Forecast and Market Analysis to 2022
|出版日期||內容資訊||英文 127 Pages
|PharmaPoint:人類乳突病毒(HPV)預防疫苗 - EU5個國家的醫藥品預測與市場分析 PharmaPoint: Prophylactic Human Papillomavirus Vaccines - 5EU Drug Forecast and Market Analysis to 2022|
|出版日期: 2014年03月31日||內容資訊: 英文 127 Pages||
The first prophylactic vaccine for immunization against human papillomavirus (HPV) became available in 2006. The global HPV vaccines market is now well established, yet vaccine coverage rates amongst the traditional target population of adolescent girls remain persistently low. Initially HPV vaccines were developed and marketed solely to protect against cervical cancer. In recent years the role of HPV in other cancers has been increasingly recognized which has facilitated a shift towards vaccinating a wider population, most significant has been the inclusion of males in routine vaccine recommendations in some countries. The current HPV vaccines market is dominated by one major player, Merck's Gardasil, with GlaxoSmithKline's (GSK's) HPV vaccine Cervarix providing the only competition. The introduction of Merck's nine-valent vaccine (V503) is set to change the future landscape of the HPV vaccines sector.
There are very low HPV vaccine coverage rates in France and GlobalData expects this to continue throughout the forecast period, especially while the burden of vaccine cost falls partially on the patient. GlobalData anticipates that the low coverage rates for HPV vaccination in Germany will persist throughout the forecast period. Although lower than for other vaccines, coverage rates for HPV vaccination in Italy are higher than for many European countries. Compared with other countries Spain has relatively high coverage rates for HPV vaccination, which GlobalData expects will persist throughout the forecast period. Due to the comprehensive nature of its school-based immunization program, the UK has high HPV vaccine coverage rates.